Healthcare -
Biotechnology - NASDAQ - US
$ 13.93
-1.12 %
$ 1.46 B
Market Cap
-9.17
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Edgewise Therapeutics, Inc.
| Net Income | -134 M |
| Depreciation & Amortization | 2.29 M |
| Capital Expenditures | -1.31 M |
| Stock-Based Compensation | 24.7 M |
| Change in Working Capital | 10.3 M |
| Others | -3.95 M |
| Free Cash Flow | -110 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (133.8) | (100.2) | (67.6) | (42.8) | (17.1) | (9.7) |
| Depreciation & Amortization | 2.3 | 1.7 | 0.5 | 0.3 | 0.2 | 0.1 |
| Deferred Income Tax | 0 | 0 | 0 | (2.3) | (0.2) | 48 K |
| Stock Based Compensation | 24.7 | 17.6 | 10.9 | 4.4 | 0.4 | 77 K |
| Other Operating Activities | (12.5) | (9.5) | (0.5) | 2.3 | 0.2 | 48 K |
| Change in Working Capital | 10.3 | (1.6) | 4.1 | 4.6 | 1.9 | 0.3 |
| Cash From Operations | (109.0) | (91.9) | (52.6) | (33.5) | (14.6) | (9.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.3) | (5.7) | (5.5) | (0.7) | (0.2) | (0.2) |
| Other Items | (183.3) | 108.6 | (65.0) | (241.6) | (24.2) | 0 |
| Cash From Investing Activities | (184.7) | 102.9 | (70.6) | (242.2) | (24.4) | (0.2) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.1 | 1.3 | 0.5 | 0.2 | 120.3 | 24.8 |
| Cash From Financing Activities | 249.3 | 53.2 | 129.6 | 186.4 | 120.3 | 24.8 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (44.4) | 64.1 | 6.4 | (89.3) | 81.3 | 15.4 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (110.3) | (97.7) | (58.2) | (34.2) | (14.8) | (9.4) |